Velocity
This Week's Stories
Boltz

Boltz

AI Drug Discovery · Biotech AI

Funding

Boltz raises $110M Series A to scale AI drug discovery models

November 18, 2026

Raised

$110M

Series A

Usage of its molecular design software has grown fifty-fold since June as top pharma firms sign on.

  • Boltz raised $110 million in a Series A led by Bessemer Venture Partners, less than a year after its $28 million seed round.
  • The London-based lab, spun out of MIT's CSAIL and Jameel Clinic, builds AI foundation models that predict and design how proteins and small molecules bind, speeding early-stage drug discovery.
  • Six of the world's 20 largest pharmaceutical companies, including Pfizer, GSK, Takeda and Bristol Myers Squibb, now use its Boltz Lab platform.
  • Molecular token usage among paying customers has grown 50-fold since June, when Boltz released its first proprietary models, BoltzMol-1 and BoltzProt-1.
  • Boltz's earlier open-source models, which match AlphaFold3's performance, have been downloaded more than 5 million times and are used by over 100,000 scientists.
  • The round signals investors betting that AI-designed molecules, not just AI-run labs, will become the default tool for early-stage drug discovery.

Lead Investors

Bessemer Venture Partners

Read More About This Story

Get the app

Stay Ahead With Velocity

Deep company profiles, investor context, and every original source behind this story — plus the next one, the moment it breaks.

Download on the App StoreGet it on Google Play

More This Week

View All →